Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Pulse Biosciences, Inc. (NASDAQ: PLSE) resulting from allegations that Pulse may have issued materially misleading business information to the investing public.

On September 11, 2017, Pulse disclosed “that it has withdrawn its initial application to the United States Food and Drug Administration (FDA) for 510(k) clearance of its PulseTxTM System.” Pulse further disclosed that the “voluntary withdrawal on September 8, 2017, was the result of the FDA’s appropriate request for additional data that could not be provided within the Agency’s 90-day review period that would have otherwise ended on September 10, 2017.” On this news, shares of Pulse fell sharply during intraday trading on September 11, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Pulse investors. If you purchased shares of Pulse, please visit the firm’s website at http://www.rosenlegal.com/cases-1209.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170911005840/en/